Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Medicine (Baltimore) ; 100(21): e26143, 2021 May 28.
Article in English | MEDLINE | ID: covidwho-2191018

ABSTRACT

INTRODUCTION: Coronavirus disease 2019 (COVID-19) is a rapidly emerging infectious respiratory disease caused by severe acute respiratory syndrome coronavirus 2. Currently, more than 100 million cases of COVID-19 have been confirmed worldwide, with over 2.4 million mortalities. The pandemic affects people of all ages but older individuals and those with severe chronic illnesses, including cancer patients, are at higher risk. PATIENT CONCERNS: The impact of cancer treatment on the progression of COVID-19 is unclear. Therefore, we assessed the effects of chemotherapy on COVID-19 outcomes for 2 cancer patients. On January 24, 2020, a level I response to a major public health emergency was initiated in Hubei Province, China, which includes Enshi Autonomous Prefecture that has a population of 4.026 million people. As of April 30, 2020, 252 confirmed cases of COVID-19 and 11 asymptomatic carriers were identified in Enshi. DIAGNOSIS: Among the confirmed cases and asymptomatic carriers, 2 patients were identified who were previously diagnosed with malignant tumors, including one with hepatocellular carcinoma and the other with cardia carcinoma. INTERVENTIONS: These 2 patients were receiving or just completed chemotherapy at the time of their COVID-19 diagnosis. OUTCOMES: Both patients were followed and presented favorable outcomes. The positive outcomes for these 2 patients could be partially explained by their recent chemotherapy that impacted their immune status. Also, their relatively younger ages and lack of comorbidities were likely factors in their successful recovery from COVID-19. CONCLUSIONS: Anticancer treatment might enhance a patient's ability to respond favorably to COVID-19 infection. However, anticancer treatment is likely to impact immune function differently in different individuals, which can influence disease outcomes.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , COVID-19/immunology , Liver Neoplasms/drug therapy , SARS-CoV-2/immunology , Stomach Neoplasms/drug therapy , Adult , COVID-19/complications , COVID-19/diagnosis , COVID-19 Nucleic Acid Testing , Cyclobutanes/therapeutic use , Docetaxel/therapeutic use , Drug Therapy, Combination/methods , Humans , Liver Neoplasms/complications , Liver Neoplasms/immunology , Lung/diagnostic imaging , Male , Middle Aged , Organoplatinum Compounds/therapeutic use , RNA, Viral/isolation & purification , SARS-CoV-2/genetics , SARS-CoV-2/isolation & purification , Sorafenib/therapeutic use , Stomach Neoplasms/complications , Stomach Neoplasms/immunology , Tomography, X-Ray Computed , Treatment Outcome
2.
RSC advances ; 12(49):31608-31616, 2022.
Article in English | EuropePMC | ID: covidwho-2112016

ABSTRACT

The excessive use of sodium hypochlorite disinfectant for preventing COVID-19 can be harmful to the water environment and humans. More importantly, owing to hypochlorite being a biomarker of immune responses in living organisms, its abnormal production can damage nucleic acids and protein molecules, eventually causing many diseases (even cancer). Exploring a reliable, rapid, and non-invasive method to monitor the hypochlorite level in vitro and in cells can be significant. Herein, we report a novel ratiometric fluorescence sensing strategy based on Astrazon Brilliant Red 4G dye-sensitized NaGdF4:Yb3+, Er3+@NaYF4 core–shell upconversion nanoparticles (UCNPs@ABR 4G). Based on the combination mechanism of the fluorescent resonant energy transfer effect (FRET) and redox, a linear model of fluorescence intensity ratio and hypochlorite concentration was constructed for a fast response and high selectivity monitoring of hypochlorite in vitro and in vivo. The detection limit was calculated to be 0.39 μM. In addition, this sensing strategy possessed good stability and circularity, making it valuable both for the quantitative detection of hypochlorite in water and for the visualization of intracellular hypochlorite. The proposed optical probe is promising for the efficient and stable non-invasive detection of hypochlorite. The excessive use of sodium hypochlorite disinfectant for preventing COVID-19 can be harmful to the water environment and humans.

3.
RSC Adv ; 12(49): 31608-31616, 2022 Nov 03.
Article in English | MEDLINE | ID: covidwho-2106534

ABSTRACT

The excessive use of sodium hypochlorite disinfectant for preventing COVID-19 can be harmful to the water environment and humans. More importantly, owing to hypochlorite being a biomarker of immune responses in living organisms, its abnormal production can damage nucleic acids and protein molecules, eventually causing many diseases (even cancer). Exploring a reliable, rapid, and non-invasive method to monitor the hypochlorite level in vitro and in cells can be significant. Herein, we report a novel ratiometric fluorescence sensing strategy based on Astrazon Brilliant Red 4G dye-sensitized NaGdF4:Yb3+, Er3+@NaYF4 core-shell upconversion nanoparticles (UCNPs@ABR 4G). Based on the combination mechanism of the fluorescent resonant energy transfer effect (FRET) and redox, a linear model of fluorescence intensity ratio and hypochlorite concentration was constructed for a fast response and high selectivity monitoring of hypochlorite in vitro and in vivo. The detection limit was calculated to be 0.39 µM. In addition, this sensing strategy possessed good stability and circularity, making it valuable both for the quantitative detection of hypochlorite in water and for the visualization of intracellular hypochlorite. The proposed optical probe is promising for the efficient and stable non-invasive detection of hypochlorite.

SELECTION OF CITATIONS
SEARCH DETAIL